Evidence map›Paper›PMID 40877872›Full record

ArticleBMC proceedings2025

Accelerating HPV-related cancer elimination - a meeting report.

F Ricardo Burdier, F Xavier Bosch, Dur-E-Nayab Waheed, Laura Teblick, Mario Poljak, Marc Baay, Silvia de Sanjosé, Marc Bardou, Iacopo Baussano, Irene Man and 2 more

Abstract read
In one paragraph

Article in BMC proceedings, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F Ricardo BurdierCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium.
F Xavier BoschUnit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia-Catalan Institute of Oncology, IDIBELL, Avenida Gran Via 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain.
Dur-E-Nayab WaheedCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium.
Laura TeblickCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium.
Mario PoljakInstitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Marc Baay, P95 Clinical & EpidemiologyServices, Louvain, Belgium.
Silvia de SanjoséISGlobal, Barcelona, Spain.
Marc BardouCIC1432, CHU Dijon Bourgogne and Université Bourgogne Europe, Dijon, France.
Iacopo BaussanoInternational Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
Irene ManInternational Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
Eduardo L FrancoMcGill University, Montreal, Canada.
Alex VorstersCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Drie Eikenstraat 663, 2650, Edegem, Belgium. alex.vorsters@uantwerpen.be.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The human papillomavirus (HPV) Prevention and Control Board organized a meeting to explore effective strategies for accelerating the elimination of HPV-related cancers, starting from WHO's cervical cancer elimination campaign targets-vaccination of 90% of girls by age 15, two HPV screenings with a high-performance test for 70% of women between 35-45 years, and 90% treatment and care of women with cervical disease. Nevertheless, the global HPV vaccination coverage remains low (~ 30%), as does screening coverage, with only 24% (48/139) of programmes utilising recommended high-performance tests (such as HPV testing). The meeting explored various strategies, including the extension of vaccination for women at older ages. While vaccination of HPV-positive individuals has demonstrated safety and immunogenicity, further research is required to confirm the potential protective effects and reduced viral transmission among infected populations. Several innovative approaches were discussed, including the HPV Faster strategy, promoting combined HPV vaccination and screening for women up to age 45. This strategy aims to substantially reduce cervical cancer incidence by decreasing future screening needs among HPV-negative women and intensifying follow-up for those already HPV-positive. A variant of this approach, Sweden's "HPV EVEN Faster," simultaneously vaccinates and screens younger women (ages 23-30), aiming at significantly reducing HPV circulation and effectively reaching underserved populations. Moreover, in resource-limited settings, transitioning to single-dose vaccination emerged as a promising strategy to expand vaccine coverage, as modelled in India, Rwanda, and Brazil. Modelling data reinforced the prioritisation of increasing vaccination coverage and expanding targets in girls up to age 20 as the most efficient strategy to reduce cervical cancers. However, when increasing coverage is challenging, extending vaccination to boys could potentially enhance herd protection. Finally, the discussions underlined that successful "accelerated" HPV elimination strategies must be context-specific, taking into consideration local resources, health system capacities, and socio-economic factors. Political commitment, targeted implementation research, and innovations such as affordable new vaccines and point-of-care tests are key to speed up global progress toward HPV-related cancer elimination.

Indexed as

Cervical cancer eliminationCervical cancer screeningHPV vaccinationHuman papillomavirus infection (HPV)

Identifiers

PMID40877872
PMCPMC12395638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.